Prostate Cancer

Data presented at 2022 ASCO GU of niraparib-based therapy for patients with metastatic castration-resistant prostate cancer showed a boost in radiographic progression-free survival vs matched placebo.

Data from the ARASENS trials that were presented at 2022 ASCO GU show superior survival outcomes with darolutamide vs placebo plus ADT and docetaxel.

The phase 3b PRESIDE trial showed significant progression-free survival improvement when men with chemotherapy-naïve metastatic castration-resistant prostate cancer were treated with a regimen of continuous enzalutamide vs placebo.

Patients with metastatic castration-sensitive prostate cancer experienced an early and robust reduction in prostate-specific antigen of 90% or more following treatment with apalutamide vs enzalutamide.

Data from the ARAMIS trial that were presented at 2022 ASCO GU showed that darolutamide benefit for patients with nonmetastatic castration-resistant prostate cancer was consistent regardless of the number of comorbidities or concomitant medications.

Eleni Efstathiou, MD, PhD, spoke about the treatment combination of niraparib plus abiraterone acetate and prednisone for the treatmeant of men with metastatic castration-resistant prostate cancer in the phase 3 MAGNITUDE trial.

Datar Cancer Genetics announced that its TriNetra-Prostate blood test, which was developed to detect early-stage prostate cancer, received breakthrough device designation from the FDA.

Patients with prostate cancer commonly have significant depression, highlighting a need for screenings in those with poor social determinants of health, concomitant disability, and advanced disease.

Patients with metastatic castration-resistant prostate cancer treated with apalutamide and prednisone experienced a better radiographic progression-free survival vs an active and established comparator regimen.

Alicia Morgans, MD, discusses genomic testing and use of PARP inhibitors for metastatic castration-resistant prostate cancer.

Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.

A meta-analysis of 2 phase 3 randomized trials found that combination therapy including androgen deprivation therapy led to higher rates of metastasis-free survival for patients with high-risk non-metastatic prostate cancer.

Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer.

The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.

The decision by the FDA to approve prostate cancer imaging product TLX591-CDx, a kit to aid in the preparation of gallium-68 gozetotide injections, should make 68Ga-based PSMA-PET more broadly accessible.

CancerNetwork® takes a deep dive into ongoing clinical research that holds promise in the prostate cancer space as the year 2021 comes to a close.

Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.

Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.

A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

The phase 3 ARASENS trial, which assessed the use of darolutamide and docetaxel in patients with metastatic hormone-sensitive prostate cancer, met its primary end point of significantly improved overall survival.

The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.